乳腺癌新辅助化疗疗效评价的相关研究

贾莉; 邓智勇; 贾莉; 邓智勇

doi:10.3760/cma.j.issn.1673-4114.2013.04.012

[1]

Garces CA, Cance WG. Neoadjuvant chem-otherapy of breast cancer. Am Surg, 2004, 70(7): 565-569.

[2]

傅健飞, 李曙光, 洪中武, 等.体检和B超以及钼靶评价乳腺癌新辅助化疗疗效的准确性研究.中国全科医学, 2010, 13(12B): 3944-3945.

[3]

刘晓婷, 马灵芝.彩色多普勒超声评价乳腺癌新辅助化疗疗效的研究.现代肿瘤医学, 2011, 19(3): 460-462.

[4]

Feldman L, Hortobagy G, Buzdar A, et al. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res, 1986, 46(5): 2578-2581.

[5]

Chagpar AB, Middleton LP, Sahin AA, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg, 2006, 243(2): 257-264.

[6]

Sperber F, Weinstein Y, Sarid D, et al. Preoperative clinical, mammographic and sonographic assessment of neoadjuvant chemotherapy response in breast cancer. Isr Med Assoc J, 2006, 8(5): 342-346.

[7]

Yeh E, Slanetz P, Kopans DB, et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. AJR Am J Roentgenol, 2005, 184(3): 868-877.

[8]

滕妍, 曹满瑞, 孙立宏, 等.全数字化乳腺X线摄影在乳腺癌新辅助化疗疗效评价上的应用.北华大学学报:自然科学版, 2009, 10(2): 133-135.

[9]

王殊, 张嘉庆, 乔新民, 等.新辅助化疗后乳腺癌病理变化31例分析.中国妇产科临床杂志, 2007, 8(4): 282-284.

[10]

孟方, 李征毅, 乔军, 等.彩色多普勒超声在乳腺癌新辅助化疗疗效评价中的应用.中国超声医学杂志, 2010, 26(7): 612-614.

[11]

陈雁威.彩色多普勒超声对乳腺癌新辅助化疗疗效的评价.实用肿瘤学杂志, 2007, 21(6): 507-508.

[12]

Singh G, Kumar P, Parshad R, et al. Role of color Doppler indices in predicting disease-free survival of breast cancer patients during neoadjuvant chemotherapy. Eur J Radiol, 2010, 75(2): 158-162.

[13]

胡静, 赵亚娥, 汪登斌, 等. MRI对浸润性乳腺癌新辅助化疗疗效的评估价值.外科理论与实践, 2011, 16(1): 29-33.

[14]

Chen JH, Feig B, Agrawal G, et al. MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy. Cancer, 2008, 112(1): 17-26.

[15]

Gilles R, Guinebretiere JM, Lucidarme O, et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology, 1994, 191(3): 625-631.

[16]

Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. Am J Roentgenol, 2002, 179(5): 1193-1199.

[17]

Rieber A, Brambs HJ, Gabelmann A, et al. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol, 2002, 12(7): 1711-1719.

[18]

关晏星, 雷秋模, 翟伟, 等. ^99mTc-MIBI显像评价乳腺癌新辅助化疗疗效.中华核医学杂志, 2006, 26(1): 36-38.

[19]

Festa A, Tofani A, Sciuto R, et al. ^99mTc-MIBI scintigraphy evaluates response to neoadjuvant chemotherapy in locally advanced breast cancer. Eur J Cancer, 1998, 34(5): 10-11.

[20]

Marshall C, Eremin J, El-Sheemy M, et al. Monitoring the response of large(> 3 cm) and locally advanced(T3-4, NO-2)breast cancer to neoadjuvant chemotherapy using ^99mTc-Sestamibi uptake. Nucl Med Commun, 2005, 26(1): 9-15.

[21]

Koga KH, Moriguchi SM, Neto JN, et al. ^99mTc-sestamibi scintigraphy used to evaluate tumor response to neoadjuvant chemotherapy in locally advanced breast cancer: A quantitative analysis. Oncol Lett, 2010, 1(2): 379-382.

[22]

Kumar A, Kumar R, Seenu V, et al. The role of ¹⁸F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. Eur Radiol, 2009, 19(6): 1347-1357.

[23]

宋武战, 池君, 汪静, 等. ¹⁸F-FDG显像在乳腺癌新辅助化疗疗效评价中的应用.临床军医杂志, 2007, 35(6): 820-822.

[24]

Zornoza G, Garcia Velloso MJ, Sola J, et al. ¹⁸F-FDG PET complemented with sentinel lymph node biopsy in the detection of axillary involvement in breast cancer. Eur J Surg Oncol, 2004, 30(1): 15-19.

[25]

蔡媛, 张晨灵, 郑甦, 等. ER、PR、C-erbB-2的表达与乳腺癌新辅助化疗疗效的关系.肿瘤基础与临床, 2010, 23(3): 223-225.

[26]

陈伟财, 王先明, 佘晓佳, 等.乳腺癌ER, PR和HER-2的表达状况与新辅助化疗疗效的临床观察.山西医科大学学报, 2010, 41(7): 599-601.

[27]

Berry DA, Cirrineionf C, Henderson IC, et al. Estrogen-receptor status and outcomes of modem chemotherapy for patients with node-positive breast cancer. JAMA, 2006, 295(14): 1658-1667.

[28]

MacGrogan G, Mauriae L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br J Cancer, 1996, 74(9): 1458-1465.

[29]

朱强, 王丕琳, 宋茂民, 等.生物标志与乳腺浸润性导管癌新辅助化疗疗效相关性的多因素分析.中华肿瘤防治杂志, 2009, 16(10): 779-781.

[30]

凡庆东, 姜军, 杨新华, 等.乳腺癌p53、cerbB-2表达与TE方案新辅助化疗疗效的关系.重庆医科大学学报, 2007, 32(10): 1059.

[31]

刘伟平, 臧家兰, 蔡莉, 等.乳腺癌生物学因子与新辅助化疗疗效的相关性分析.放射免疫学杂志, 2009, 22(1): 82-85.

[32]

卫燕, 李金峰, 王天峰, 等.激素受体和Ki67的表达与乳腺癌蒽环类新辅助化疗疗效的相关性.北京大学学报:医学版, 2007, 39(5): 481-483.

[33]

肖宇, 李惠平, 雷玉涛, 等.乳腺癌新辅助化疗疗效及ER/PR, HER2, Ki67, CyclinA2的化疗预测作用.中国微创外科杂志. 2011, 11(2): 163-167.

[34]

薛静彦.预测乳腺癌新辅助化疗疗效的多基因表达谱研究进展.中国癌症杂志, 2010, 20(12): 941-945.

[35]

Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocol B-18 and B-27. J Clin Oncol, 2008, 26(5): 778-785.